These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
827 related articles for article (PubMed ID: 31298061)
1. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria. Doymaz MZ; Karaaslan E Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061 [No Abstract] [Full Text] [Related]
2. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria. Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003 [TBL] [Abstract][Full Text] [Related]
3. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates]. Akin FE; Bayram A; Balci I Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954 [TBL] [Abstract][Full Text] [Related]
4. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821 [TBL] [Abstract][Full Text] [Related]
6. Performances of the Rapid Polymyxin Lescat M; Poirel L; Jayol A; Nordmann P Microb Drug Resist; 2019 May; 25(4):520-523. PubMed ID: 30508392 [No Abstract] [Full Text] [Related]
7. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342 [TBL] [Abstract][Full Text] [Related]
8. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Ardebili A; Izanloo A; Rastegar M Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511 [TBL] [Abstract][Full Text] [Related]
9. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Vidaillac C; Benichou L; Duval RE Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. Zhang Y; Zhao C; Wang Q; Wang X; Chen H; Li H; Zhang F; Wang H J Antimicrob Chemother; 2020 Sep; 75(9):2609-2615. PubMed ID: 32591806 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care centre in Western Turkey. Ece G; Samlioglu P; Atalay S; Kose S Infez Med; 2014 Mar; 22(1):36-40. PubMed ID: 24651089 [TBL] [Abstract][Full Text] [Related]
12. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Sader HS; Rhomberg PR; Farrell DJ; Jones RN Diagn Microbiol Infect Dis; 2015 Dec; 83(4):379-81. PubMed ID: 26415906 [TBL] [Abstract][Full Text] [Related]
13. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates. Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217 [TBL] [Abstract][Full Text] [Related]
15. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. Gales AC; Reis AO; Jones RN J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Etest method for detecting colistin susceptibility of multidrug-resistant Gram-negative isolates in Vietnam. Nhung PH; Miyoshi-Akiyama T; Phuong DM; Shimada K; Anh NQ; Binh NG; Thanh do V; Ohmagari N; Kirikae T J Infect Chemother; 2015 Aug; 21(8):617-9. PubMed ID: 25960156 [TBL] [Abstract][Full Text] [Related]
20. Diclofenac Sodium Restores the Sensitivity of Colistin-Resistant Gram-Negative Bacteria to Colistin. Fu Q; Liu S; Hu P; Chen H; Zheng J; Shi S; Xu M; Zhou T; Sun Y ACS Infect Dis; 2024 Aug; 10(8):2860-2869. PubMed ID: 39073350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]